AssetMark Inc’s Royalty Pharma RPRX Stock Holding History

AssetMark Inc’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.82M	Buy	31,155 +20,285	+187%	+$1.2M	﹤0.01%	976
2026 Q2	$610K	Buy	10,870 +5,012	+86%	+$261K	﹤0.01%	1189
2026 Q1	$281K	Buy	5,858 +2,170	+59%	+$95K	﹤0.01%	1270
2025 Q4	$143K	Buy	3,688 +168	+5%	+$6.41K	﹤0.01%	1387
2025 Q3	$124K	Buy	3,520 +216	+7%	+$7.82K	﹤0.01%	1374
2025 Q2	$119K	Buy	3,304 +2,696	+443%	+$89.3K	﹤0.01%	1333
2025 Q1	$18.9K	Buy	608 +270	+80%	+$8.56K	﹤0.01%	1718
2024 Q4	$8.62K	Buy	338 +319	+1,679%	+$8.46K	﹤0.01%	1820
2024 Q3	$538	Buy	+19	New	+$526	﹤0.01%	2076
2024 Q1	–	Sell	-9	Closed	-$253	–	2088
2023 Q4	$253	Buy	+9	New	+$247	﹤0.01%	1739
2022 Q4	–	Sell	-83	Closed	-$3K	–	1651
2022 Q3	$3K	Buy	+83	New	+$3.54K	﹤0.01%	1364

Other funds holding RPRX

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $53.6B AUM 32.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

AssetMark Inc's RPRX Position: Q3 2026 in Review

AssetMark Inc increased its Royalty Pharma (RPRX) stake by 187% in Q3 2026, buying an estimated $1.2M and bringing the position to 31,155 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #976.

AssetMark Inc first reported a position in RPRX in Q3 2022 and has held it in 11 quarters since. 272 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

AssetMark Inc held 31,155 shares of Royalty Pharma worth $1.82M as of Q3 2026.
AssetMark Inc bought 20,285 Royalty Pharma shares in Q3 2026, an estimated $1.2M.
Royalty Pharma made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #976 holding.
AssetMark Inc first reported a position in Royalty Pharma in Q3 2022 and has held it in 11 quarters since.
272 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.